OralParenteralDosed ingredient Cosmetic cross-reference

Pyridoxine

CAS 65-23-6

Pyridoxine (CAS 65-23-6) is a Phase 4 pharmaceutical compound with 6 bioactivity targets and 5,395 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

5,395

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Pyridoxine

CAS Number

65-23-6

UNII

KV2JZ1BI6Z

InChIKey

LXNHXLLTXMVWPM-UHFFFAOYSA-N

ChEMBL ID

CHEMBL1364

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural productoralparenteral

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1364 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 9 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	27888.885294117645 nM	34	-
-	Potency	17013.82 nM	5	-
-	IC50	19976.309999999998 nM	1	-
Serine hydroxymethyltransferase, cytosolic Enzyme	-	-	-	Homo sapiens
Pyridoxine-5'-phosphate oxidase Enzyme	-	-	-	Homo sapiens
Pyridoxal phosphate phosphatase Enzyme	-	-	-	Homo sapiens
Pyridoxal kinase Kinase	-	-	-	Homo sapiens
Cystathionine beta-synthase Enzyme	-	-	-	Homo sapiens
Phosphoserine aminotransferase Enzyme	-	-	-	Homo sapiens

SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Pemphigus	5388	2486.847	10034280
Systemic lupus erythematosus	5735	2413.003	10042945
Glossodynia	4963	2104.953	10018388
Hand deformity	4329	1765.582	10061194
Arthropathy	5600	1644.841	10003285
Rheumatoid arthritis	5955	1612.913	10039073
Alopecia	6837	1570.757	10001760
Abdominal discomfort	6976	1525.817	10000059
Wound	4189	1431.867	10052428
Completed suicide	164	1423.078	10010144
Maternal exposure during pregnancy	4794	1417.551	10071408
Toxicity to various agents	1076	1409.108	10070863
Synovitis	4240	1203.383	10042868
Swelling	5597	1118.163	10042674
Joint swelling	6452	1116.497	10023232
Anti-cyclic citrullinated peptide antibody positive	2939	1092.953	10068798
Contraindicated product administered	4745	1080.834	10078504
Discomfort	3841	1047.775	10013082
Pain	12390	1040.689	10033371
Pericarditis	3240	1020.56	10034484
Infusion related reaction	5408	979.631	10051792
Drug abuse	129	959.624	10013654
Arthralgia	9831	805.414	10003239
Death	3694	797.919	10011906
Drug interaction	1678	774.606	10013710
Duodenal ulcer perforation	2093	688.232	10013849
Helicobacter infection	2162	664.016	10054263
Rheumatoid factor positive	1968	655.928	10039080
Exposure during pregnancy	3068	636.274	10073513
Intentional overdose	119	631.335	10022523
Psoriatic arthropathy	2250	626.912	10037162
Hepatic enzyme increased	3921	612.482	10060795
Musculoskeletal stiffness	3724	594.067	10052904
Product use issue	4433	540.105	10076309
Drug intolerance	5302	538.588	10061822
Acute kidney injury	2724	531.564	10069339
Febrile neutropenia	875	526.871	10016288
Therapeutic product effect decreased	3562	483.737	10082201
Overdose	725	442.86	10033295
Nasopharyngitis	4419	399.525	10028810
Suicide attempt	186	367.759	10042464
Knee arthroplasty	1270	365.827	10023469
Treatment failure	3611	358.243	10066901
Disease progression	974	355.562	10061818
Hip arthroplasty	1139	352.36	10020096
Hypersensitivity	4649	340.065	10020751
Cardiac arrest	646	338.109	10007515
Foetal exposure during pregnancy	1847	319.933	10071404
Impaired healing	1930	309.017	10021519
Depressed level of consciousness	247	308.175	10012373

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE RxNorm drug names 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
PYRIDOXINE	684879	SU	MTHSPL
Pyridoxine	684879	SU	MTHSPL
pyridoxine	684879	IN	RXNORM

SOURCE SIDER side-effect resource 10 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Headache	pyridoxine	LLT	C0018681
Headache	pyridoxine	PT	C0018681
Nausea	pyridoxine	LLT	C0027497
Nausea	pyridoxine	PT	C0027497
Neuropathy peripheral	pyridoxine	LLT	C0031117
Neuropathy peripheral	pyridoxine	PT	C0031117
Paraesthesia	pyridoxine	LLT	C0030554
Paraesthesia	pyridoxine	PT	C0030554
Somnolence	pyridoxine	LLT	C2830004
Somnolence	pyridoxine	PT	C2830004

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Pyridoxine used for in pharmaceutical contexts?

Pyridoxine (CAS 65-23-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Pyridoxine?

Pyridoxine has 5,395 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Hand deformity, Arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Pyridoxine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Pyridoxine with EU status "permitted".

What clinical phase is Pyridoxine in?

Pyridoxine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Pyridoxine?

Pyridoxine has 9 bioactivity rows in this page query. Rendered target entries include Serine hydroxymethyltransferase, cytosolic, Pyridoxine-5'-phosphate oxidase, Pyridoxal phosphate phosphatase, Pyridoxal kinase, Cystathionine beta-synthase.